ArticleLancet regional health. Americas2022
Prognostic factors of
Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical Characteristics, Diagnosis, and Treatment of Central Nervous System Candidiasis: A Systematic Review of 418 Cases.Mycopathologia · 2026Pooled it
- Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.Mycopathologia · 2024Pooled it
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.The Journal of antimicrobial chemotherapy · 2023Trial
- Preventive action of ketamine alone and in combination with antifungals on Candida biofilm formation in catheters.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Article
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Genome sequences of six clinical isolates ofMicrobiology resource announcements · 2025Article
- Medical Mycology Education in Brazil: A Cross-Sectional Survey of Medical Schools.Open forum infectious diseases · 2025Article
- In Vitro Fluconazole Exposure Promotes Switch Phenotypes With Altered Virulence Traits in the Pathogenic YeastIndian journal of microbiology · 2025Article
- Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC infectious diseases · 2025Article
- Candida albicans Recovered From Persistent Candidemia Exhibits Enhanced Virulence Traits.The Journal of infectious diseases · 2025Article
- Candidemia in ICU Patients: What Are the Real Game-Changers for Survival?Journal of fungi (Basel, Switzerland) · 2025Article
- Higher caloric intake through enteral nutrition is associated with lower hospital mortality rates in patients with candidemia and shock in Taiwan.Acute and critical care · 2024Article
- Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of amSphere · 2024Article
- Antifungal susceptibility and virulence determinants profile of candida species isolated from patients with candidemia.Scientific reports · 2024Article
- Guideline Adherence and Outcomes of Patients with Candidemia in Brazil.Journal of fungi (Basel, Switzerland) · 2024Article
- Epidemiological Assessment and Risk Factors for Mortality of Bloodstream Infections byJournal of fungi (Basel, Switzerland) · 2024Article
- Anti-Candida Antibodies of Patients with Invasive Candidiasis Inhibit Growth, Alter Cell Wall Structure, and Kill Candida albicans In Vitro.Mycopathologia · 2024Article
- Antifungal Effect of ProbioticJournal of dentistry (Shiraz, Iran) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mortality rates among adults with candidemia vary widely in different geographical settings. Studies directly comparing epidemiology and clinical practices between countries are scarce and could bring insights into improving clinical outcomes. Methods: Retrospective cohort including adults with candidemia diagnosed in five tertiary hospitals from Brazil and Spain between 2010-2018. Adequate therapeutic management included appropriate antifungal therapy and central-venous-catheter (CVC) removal within 48 h of fungemia. Primary endpoints were mortality rates at 14 and 30 days. Secondary endpoints were prognostic factors associated with 30-day mortality. Findings: Overall, 720 patients were included, being 323 from Spain. Spanish patients received echinocandins more often (52·5% vs. 39·3%, Interpretation: Higher mortality rates were observed in Brazil. Factors associated with 30-day mortality included mainly epidemiological characteristics and inadequate therapeutic management. Thus, effective and prompt antifungals combined with CVC-removal still need to be emphasized in order to improve the prognosis of adults with candidemia. Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2017/02203-7); CAPES Foundation (PDSE 88881.187981/2018-01).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.